NCT01305499View on ClinicalTrials.gov

A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 1, 2011

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2024

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Entinostat days 3, 10

Given orally on days 3, 10

DRUG

5AC

DRUG

Entinostat days 10,17

Given orally on days 10, 17

Trial Locations (4)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

44106

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland

06520

Yale School of Medicine, New Haven

All Listed Sponsors
lead

Hetty Carraway

OTHER